Daily Briefing

3 minute read

Around the nation: Hims & Hers teams up with Eli Lilly on GLP-1s


Hims & Hers is partnering with Eli Lilly to offer access to the drugmaker's branded GLP-1 medications as part of its ongoing shift away from compounded versions of the drugs, in today's bite-sized hospital and health industry news from California, Illinois, and Ohio. 

  • California: Hims & Hers is partnering with Eli Lilly to offer access to the drugmaker's branded GLP-1 medications. Under the agreement, Lilly will give Hims' pharmacies direct access to its GLP-1 drugs, Zepbound and Foundayo. Previously, the drugs were only available to Hims patients if they left the site and used Lilly's direct-to-consumer platform LillyDirect. "Lilly is one of the most innovative pharmaceutical companies in history, and I'm incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they've created," said Andrew Dudum, co-founder and CEO of Hims & Hers. The partnership with Lilly is similar to the one Hims set up with Novo Nordisk earlier this year. Novo's branded GLP-1 drugs, Wegovy and Ozempic, are also available on the Hims platform. Recently, Hims has shifted its obesity strategy away from cheaper compounded GLP-1s to FDA-approved branded GLP-1 treatments, Fierce Healthcare reports. This decision has increased financial pressure on the company, with Hims posting a $92 million loss in Q1 and an $86 million loss in Q2, including $81 million in one-time costs. (Landi, Fierce Healthcare, 11/6)
  • Illinois: According to a new study published in JAMA Pediatrics, cases of infant bleeding increased significantly in 2025 as more parents rejected vitamin K injections for their newborns. Vitamin K helps the body form blood clots, but newborns don't have enough of it at birth and cannot receive enough through breastmilk. Because of this, infants deficient in vitamin K have a risk of uncontrollable bleeding and stroke. In the study, researchers found that cases of vitamin K-deficient bleeding in infants increased from 189 in 2017 to 903 in 2024. Then in 2025, the number of cases nearly doubled, reaching 1,764 cases of vitamin K-deficient bleeding. Of these cases, a majority of infants had not received vitamin K shots, and a small percentage of cases led to brain hemorrhages. According to the researchers, the rise in parents refusing vitamin K shots for their newborns and of bleeding incidents aligns with growing vaccine skepticism. Although the vitamin K shot is not a vaccine, some parents believe it is one since it is given as an injection. "We've gone generations without seeing this kind of increase in complications," said Steven Woolf, a professor of family medicine and population health at Virginia Commonwealth University and one of the study's authors. "It's very disheartening to see that progress in public health rolling back." (Wu, Washington Post, 11/5)
  • Ohio: Premier Health has named Rosanna Morris as its next president and CEO. Morris succeeds Michael Riordan, who announced in May that he planned to retire. Currently, Morris is EVP and chief clinical operating officer at the University of Texas MD Anderson Cancer Center. Before that, she was president of Beaumont Hospital-Royal Oak and held executive leadership positions at Nebraska Medicine. She will join Premier Health as president and CEO in the first quarter of 2027. "Rosanna is a talented leader whose experience spans some of the country's most respected academic healthcare organizations," said Jason Mahoney, chair of the Premier Health Board of Trustees and chair of the CEO selection committee. "As Premier Health continues to advance its mission, Rosanna's leadership experience, strategic vision, and commitment to people uniquely position her to lead our next chapter." (Kacik, Modern Healthcare, 10/22; Premier Health news release, 10/22)

SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.